SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Panel Splits On Abbott Laboratories Diet Drug Ban

September 16, 2010 | 
1 min read
(Reuters) - A U.S. advisory panel was divided over whether to recommend banning Abbott Laboratories' (ABT.N) controversial weight-loss drug on Wednesday, although most agreed that the drug's heart risk cast a shadow on its future use.
FDA Approvals
Abbott Laboratories
MORE ON THIS TOPIC
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Human resource management and recruitment concept. Job rotation or staff turnover icon.
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Cancer of the brain as tumor growth diagnosis and symptoms of gliomas meningiomas astrocytomas and oligodendrogliomas as diagnosis of symptoms as a paper sculpture.
Alzheimer’s disease
Roche, Lilly Win First FDA Nod for Alzheimer’s Blood Test for Primary Care Use
October 14, 2025
 · 
2 min read
 · 
Tristan Manalac